Future Prospects for Helicobacter pylori Vaccination

  • Dominique Velin
  • Pierre Michetti

Current Therapies of Helicobacter Infection

Helicobacter pylori eradication therapies have revolutionized the natural course of peptic ulcer disease. Antibiotic treatment of H. pylori infection is relatively successful—the organism is eradicated in approximately 80% of patients. Numerous studies have suggested that the yearly relapse rate of 80% for duodenal ulcer and 60% for gastric ulcer is reduced to less than 5% after successful H. pylori eradication (Nervi et al. 2006). Eradication of H. pylori is strongly recommended in duodenal and gastric ulcer disease, mucosa-associated lymphoid tissue lymphoma, atrophic gastritis, postgastric cancer resection, and in first-degree relatives of gastric cancer patients (Malfertheiner et al. 2007). Triple therapy, consisting of two antibiotics— clarithromycin and amoxicillin or metronidazole—in combination with a proton pump inhibitor, has become the first-line option for infection with H. pyloriand has been recommended at several consensus...


Pylorus Infection Pylorus Eradication Gastric Epithelial Cell Pylorus Strain Vaccine Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aebischer, T., Bumann, D., Epple, H. D., Graham, D. Y., Metzger, W., Schneider, T., Stolte, M., Zeitz, M., and Meyer, T. F. (2005). Development of a vaccine against Helicobacter pylori [abstract]. Helicobacter. 10:547.Google Scholar
  2. Aebischer, T., Laforsch, S., Hurwitz, R., Brombacher, F., and Meyer, T. F. (2001). Immunity against Helicobacter pylori: significance of interleukin-4 receptor alpha chain status and gender of infected mice. Infect Immun. 69:556–558.PubMedCrossRefGoogle Scholar
  3. Akhiani, A. A., Schon, K., Franzen, L. E., Pappo, J., and Lycke, N. (2004). Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol. 172:5024–5033.PubMedGoogle Scholar
  4. Akhiani, A. A., Stensson, A., Schon, K., and Lycke, N. (2006). The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand J Immunol. 63:97–105.PubMedCrossRefGoogle Scholar
  5. Angelakopoulos, H., and Hohmann, E. L. (2000). Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun. 68:2135–2141.PubMedCrossRefGoogle Scholar
  6. Banerjee, S., Medina-Fatimi, A., Nichols, R., Tendler, D., Michetti, M., Simon, J., Kelly, C. P., Monath, T. P., and Michetti, P. (2002). Safety and efficacy of low dose Escherichia coli enter-otoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 51:634–640.PubMedCrossRefGoogle Scholar
  7. Belkaid, Y., Blank, R. B., and Suffia I. (2006). Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol Rev. 212:287–300.PubMedCrossRefGoogle Scholar
  8. Boncristiano, M., Paccani, S. R., Barone, S., Ulivieri, C., Patrussi, L., Ilver, D., Amedei, A., D'Elios, M. M., Telford, J. L., and Baldari, C. T. (2003). The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med. 198:1887–1897.PubMedCrossRefGoogle Scholar
  9. Brandtzaeg, P. (2007). Induction of secretory immunity and memory at mucosal surfaces. Vaccine. 25(30):5467–5484.PubMedCrossRefGoogle Scholar
  10. Bumann, D., Metzger, W. G., Mansouri, E., Palme, O., Wendland, M., Hurwitz, R., Haas, G., Aebischer, T., von Specht, B. U., and Meyer, T. F. (2001). Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine. 20:845–852.PubMedCrossRefGoogle Scholar
  11. Corthesy, B., Boris, S., Isler, P., Grangette, C., and Mercenier, A. (2005). Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis. J Infect Dis. 192:1441–1449.PubMedCrossRefGoogle Scholar
  12. Corthesy-Theulaz, I. E., Hopkins, S., Bachmann, D., Saldinger, P. F., Porta, N., Haas, R., Zheng-Xin, Y., Meyer, T., Bouzourene, H., Blum, A. L., and Kraehenbuhl, J. P. (1998). Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun. 66:581–586.PubMedGoogle Scholar
  13. Corthesy-Theulaz, I., Porta, N., Glauser, M., Saraga, E., Vaney, A. C., Haas, R., Kraehenbuhl, J. P., Blum, A. L., and Michetti, P. (1995). Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology. 109:115–21.PubMedCrossRefGoogle Scholar
  14. Cryz, S. J. (1993). Post-marketing experience with live oral Ty21a vaccine. Lancet. 341:49–50.PubMedCrossRefGoogle Scholar
  15. Czinn, S. J., Cai, A., and Nedrud, J. G. (1993). Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine. 11:637–642.PubMedCrossRefGoogle Scholar
  16. Del Giudice, G., Covacci, A., Telford, J. L., Montecucco, C., and Rappuoli, R. (2001). The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol. 19:523–563.PubMedCrossRefGoogle Scholar
  17. DiPetrillo, M. D., Tibbetts, T., Kleanthous, H., Killeen, K. P., and Hohmann, E. L. (1999). Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine. 18:449–459.PubMedCrossRefGoogle Scholar
  18. Di Tommaso, A., Xiang, Z., Bugnoli, M., Pileri, P., Figura, N., Bayeli, P. F., Rappuoli, R., Abrignani, S., and De Magistris, M. T. (1995). Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies. Infect Immun. 63:1102–1106.PubMedGoogle Scholar
  19. Dixon, M. F., Genta, R. M., Yardley, J. H., and Correa, P. (1996). Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 20:1161–1181.PubMedCrossRefGoogle Scholar
  20. Doidge, C., Crust, I., Lee, A., Buck, F., Hazell, S., and Manne, U. (1994). Therapeutic immunisation against Helicobacter infection. Lancet. 343:914–915.PubMedCrossRefGoogle Scholar
  21. Dubois, A., Fiala, N., Heman-Ackah, L. M., Drazek, E. S., Tarnawski, A., Fishbein, W. N., Perez-Perez, G. I., and Blaser, M.J. (1994). Natural gastric infection with Helicobacter pylori in monkeys: a model for spiral bacteria infection in humans. Gastroenterology. 106:1405–1417.PubMedGoogle Scholar
  22. Dunkley, M. L., Harris, S. J., McCoy, R. J., Musicka, M. J., Eyers, F. M., Beagley, L. G., Lumley, P. J., Beagley, K. W., and Clancy, R. L. (1999). Protection against Helicobacter pylori infection by intestinal immunisation with a 50/52-kDa subunit protein. FEMS Immunol Med Microbiol. 24:221–225.PubMedCrossRefGoogle Scholar
  23. Eaton, K. A., and Krakowka S. (1994). Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infect Immun. 62:3604–3607.PubMedGoogle Scholar
  24. Eaton, K. A., Suerbaum, S., Josenhans, C., and Krakowka, S. (1996). Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes. Infect Immun. 64:2445–2448.PubMedGoogle Scholar
  25. Ermak, T. H., Giannasca, P. J., Nichols, R., Myers, G. A., Nedrud, J., Weltzin, R., Lee, C. K., Kleanthous, H., and Monath, T. P. (1998). Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med. 188:2277–2288.PubMedCrossRefGoogle Scholar
  26. Ernst, P. B., and Gold, B. D. (2000). The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Ann Rev Microbiol. 54:615–640.CrossRefGoogle Scholar
  27. Feldman, R. A. (2001). Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori. In: Achtman, M., and Suerbaum, S., editors. Helicobacter pylori: molecular and cellular biology. Wymondham: Horizon Scientific Press; pp. 29–51.Google Scholar
  28. Ferrero, R. L., and Labigne, A. (1993). Cloning, expression and sequencing of Helicobacter felis urease genes. Mol Microbiol. 9:323–333.PubMedCrossRefGoogle Scholar
  29. Ferrero, R. L., Thiberge, J. M., Kansau, I., Wuscher, N., Huerre, M., and Labigne, A. (1995). The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA. 92:6499–6503.PubMedCrossRefGoogle Scholar
  30. Garhart, C. A., Redline, R. W., Nedrud, J. G., and Czinn, S. J. (2002). Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect Immun. 70:3529–3538.PubMedCrossRefGoogle Scholar
  31. Gebert, B., Fischer, W., Weiss, E., Hoffmann, R., and Haas, R. (2003). Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science. 301:1099–1102.PubMedCrossRefGoogle Scholar
  32. Gewirtz, A. T., Yu, Y., Krishna, U. S., Israel, D. A., Lyons, S. L., and Peek, R. M. (2004). Helicobacter pylori flagellin evades Toll-like receptor 5-mediated innate immunity. J Infect Dis 189:1914–1920.PubMedCrossRefGoogle Scholar
  33. Ghendon, Y., and Robertson, S. E. (1994). Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ. 72:973–983.PubMedGoogle Scholar
  34. Ghiara, P., Marchetti, M., Blaser, M. J., Tummuru, M. K., Cover, T. L., Segal, E. D., Tompkins, L. S., and Rappuoli, R. (1995). Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immun. 63:4154–4160.PubMedGoogle Scholar
  35. Ghiara, P., Rossi, M., Marchetti, M., Di Tommaso, A., Vindigni, C., Ciampolini, F., Covacci, A., Telford, J. L., De Magistris, M. T., Pizza, M., Rappuoli, R., and Del Giudice, G. (1997). Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun. 65:4996–5002.PubMedGoogle Scholar
  36. Gluck, R., Mischler, R., Durrer, P., Furer, E., Lang, A. B., Herzog, C., and Cryz, S. J. (2000). Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis. 181:1129–1132.PubMedCrossRefGoogle Scholar
  37. Goodman, K. J., Correa, P., Tengana Aux, H. J., Ramirez, H., DeLany, J. P., Guerrero, P. O., Lopez, Q. M., and Collazos, P. T. (1996). Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol. 144:290–299.PubMedGoogle Scholar
  38. Gomez-Duarte, O. G., Lucas, B., Yan, Z. X., Panthel, K., Haas, R., and Meyer, T. F. (1998). Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine. 16:460–471.PubMedCrossRefGoogle Scholar
  39. Gottwein, J. M., Blanchard, T. G., Targoni, O. S., Eisenberg, J. C., Zagorski, B. M., Redline, R. W., Nedrud, J. G., Tary-Lehmann, M., Lehmann, P. V., and Czinn, S. J. (2001). Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis. 184:308–314.PubMedCrossRefGoogle Scholar
  40. Graham, D. Y., Opekun, A. R., Osato, M. S., El-Zimaity, H. M., Lee, C. K., Yamaoka, Y., Qureshi, W. A., Cadoz, M., and Monath, T. P. (2004). Challenge model for Helicobacter pylori infection in human volunteers. Gut. 53:1235–1243.PubMedCrossRefGoogle Scholar
  41. Guruge, J. L., Falk, P. G., Lorenz, R. G., Dans, M., Wirth, H. P., Blaser, M. J., Berg, D. E., and Gordon, J. I. (1998). Epithelial attachment alters the outcome of Helicobacter pylori infection. Proc Natl Acad Sci USA. 95:3925–3930.PubMedCrossRefGoogle Scholar
  42. Hatzifoti, C., Roussel, Y., Harris, A. G., Wren, B. W., Morrow, J. W., and Bajaj-Elliott, M. (20066). Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter. 11:113–122.CrossRefGoogle Scholar
  43. Hayashi, S., Sugiyama, T., Yokota, K., Isogai, H., Isogai, E., Oguma, K., Asaka, M., Fujii, N., and Hirai, Y. (1998). Analysis of immunoglobulin A antibodies to Helicobacter pylori in serum and gastric juice in relation to mucosal inflammation. Clin Diagn Lab Immunol. 5:617–621.PubMedGoogle Scholar
  44. Hazell, S. L., Lee, A., Brady, L., and Hennessy, W. (1986). Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis. 153:658–663.PubMedGoogle Scholar
  45. Ikewaki, J., Nishizono, A., Goto, T., Fujioka, T., and Mifune, K. (2000). Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol Immunol. 44:29–39.PubMedGoogle Scholar
  46. Ismail, H. F., Fick, P., Zhang, J., Lynch, R. G., and Berg, D. J. (2003a). Depletion of neutrophils in IL-10(−/−) mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter. J Immunol. 170:3782–3789.Google Scholar
  47. Ismail, H. F., Zhang, J., Lynch, R. G., Wang, Y., and Berg, D. J. (2003b). Role for complement in development of Helicobacter-induced gastritis in interleukin-10-deficient mice. Infect Immun. 71:7140–7148.CrossRefGoogle Scholar
  48. Kabir, S. (2007). The current status of Helicobacter pylori vaccines: a review. Helicobacter. 12:89–102.PubMedCrossRefGoogle Scholar
  49. Kang, Q. Z., Duan, G. C., Fan, Q. T., and Xi, Y. L. (2005). Fusion expression of Helicobacter pylori neutrophil-activating protein in E. coli. World J Gastroenterol. 11:454–456.PubMedGoogle Scholar
  50. Keenan, J., Oliaro, J., Domigan, N., Potter, H., Aitken, G., Allardyce, R., and Roake, J. (2000). Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect Immun. 68:3337–3343.PubMedCrossRefGoogle Scholar
  51. Kim, B. O., Shin, S. S., Yoo, Y. H., and Pyo, S. (2001). Peroral immunization with Helicobacter pylori adhesin protein genetically linked to cholera toxin A2B subunits. Clin Sci (Lond). 100:291–298.CrossRefGoogle Scholar
  52. Kotloff, K. L., Sztein, M. B., Wasserman, S. S., Losonsky, G. A., DiLorenzo, S. C., and Walker, R.I. (2001). Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun. 69:3581–3590.PubMedCrossRefGoogle Scholar
  53. Kreiss, C., Buclin, T., Cosma, M., and Michetti, P. (1996). Safety of oral immunization with recombinant urease in patients with Helicobacter pylori infection. Lancet. 347:1630–1631.PubMedCrossRefGoogle Scholar
  54. Lee, A., Fox, J. G., Otto, G., and Murphy, J. (1990). A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology. 99:1315–1323.PubMedGoogle Scholar
  55. Lee, A., O'Rourke, J., De Ungria, M. C., Robertson, B., Daskalopoulos, G., and Dixon, M. F. (1997). A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology. 112:1386–1397.PubMedCrossRefGoogle Scholar
  56. Lee, C. K., Soike, K., Giannasca, P., Hill, J., Weltzin, R., Kleanthous, H., Blanchard, J., and Monath, T. P. (1999a). Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine. 17:3072–3082.CrossRefGoogle Scholar
  57. Lee, C. K., Soike, K., Hill, J., Georgakopoulos, K., Tibbitts, T., Ingrassia, J., Gray, H., Boden, J., Kleanthous, H., Giannasca, P., Ermak, T., Weltzin, R., Blanchard, J., and Monath, T. P. (1999b). Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine. 17:1493–1505.CrossRefGoogle Scholar
  58. Lee, C. K., Weltzin, R., Thomas, W., Jr., Kleanthous, H., Ermak, T. H., Soman, G., Hill, J. E., Ackerman, S. K., and Monath, T. P. (1995). Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis. 172:161–172.PubMedGoogle Scholar
  59. Levine, M. M., Kaper, J. B., Black, R. E., and Clements, M. L. (1983). New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev. 47:510–550.PubMedGoogle Scholar
  60. Lindholm, C., Quiding-Jarbrink, M., Lonroth, H., Hamlet, A., and Svennerholm, A. M. (1998). Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun. 66: 5964–5971.PubMedGoogle Scholar
  61. Losonsky, G. A., Kotloff, K. L., and Walker, R. I. (2003). B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals. Vaccine. 21:562–565.PubMedCrossRefGoogle Scholar
  62. Lundgren, A., Stromberg, E., Sjoling, A., Lindholm, C., Enarsson, K., Edebo, A., Johnsson, E., Suri-Payer, E., Larsson, P., Rudin, A., Svennerholm, A. M., and Lundin, B. S. (2005). Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun. 73:523–531.PubMedCrossRefGoogle Scholar
  63. Lundgren, A., Suri-Payer, E., Enarsson, K., Svennerholm, A. M., and Lundin, B. S. (2003). Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun. 71:1755–1762.PubMedCrossRefGoogle Scholar
  64. Malfertheiner, P., Megraud, F., O'morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, T., Vakil, N., and Kuipers, E. J. (2007). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 56:772–781.PubMedCrossRefGoogle Scholar
  65. Malfertheiner, P., Schultze, V., Del Giudice, G., Rosenkranz, B., Kaufmann, S. H. E.,. Winau, F, Ulrichs, T., Theophil, E., Jue, C. P., Novicki, D., Norelli, F., Contorni, M., Berti, D., Lin, J. S., Schwenke, C., Goldman, M., Tornese, D., Ganju, J., Palla, E., Rappuoli, R., and Scharschmidt, B. (2002). Phase I safety and immunogenicity of a three-component H. pylori vaccine. Gastroenterology 122 Suppl A-585, Abstr. W1195.Google Scholar
  66. Marchetti, M., Arico, B., Burroni, D., Figura, N., Rappuoli, R., and Ghiara P. (1995). Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science. 267:1655–1658.PubMedCrossRefGoogle Scholar
  67. Marchetti, M., Rossi, M., Giannelli, V., Giuliani, M. M., Pizza, M., Censini, S., Covacci, A., Massari, P., Pagliaccia, C., Manetti, R., Telford, J. L., Douce, G., Dougan, G., Rappuoli, R., and Ghiara, P. (1998). Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine. 16:33–37.PubMedCrossRefGoogle Scholar
  68. Marshall, B., and Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 323:1311–1315.CrossRefGoogle Scholar
  69. Mattsson, A., Quiding-Jarbrink, M., Lonroth, H., Hamlet, A., Ahlstedt, I., and Svennerholm, A. (1998). Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect Immun. 66:2705–2712.PubMedGoogle Scholar
  70. McAtee, C. P., Lim, M. Y., Fung, K., Velligan, M., Fry, K., Chow, T., and Berg, D. E. (1998). Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by two-dimensional gel electrophoresis, sequence analysis, and serum profiling. Clin Diagn Lab Immunol. 5:537–542.PubMedGoogle Scholar
  71. Megraud, F. (2004). H pylori antibiotic resistance prevalence, importance, and advances in testing. Gut. 53:1374–1384.PubMedCrossRefGoogle Scholar
  72. Metzger, W. G., Mansouri, E., Kronawitter, M., Diescher, S., Soerensen, M., Hurwitz, R., Bumann, D., Aebischer, T., Von Specht, B. U., and Meyer, T. F. (2004). Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine. 22:2273–2277.PubMedCrossRefGoogle Scholar
  73. Michetti, P., Corthesy-Theulaz, I., Davin, C., Haas, R., Vaney, A. C., Heitz, M., Bille, J., Kraehenbuhl, J. P., Saraga, E., and Blum, A. L. (1994). Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology. 107:1002–1011.PubMedGoogle Scholar
  74. Michetti, M., Kelly, C. P., Kraehenbuhl, J. P., Bouzourene, H., and Michetti, P. (2000). Gastric mucosal alpha(4)beta(7)-integrin-positive CD4 T lymphocytes and immune protection against Helicobacter infection in mice. Gastroenterology. 119:109–118.PubMedCrossRefGoogle Scholar
  75. Michetti, P., Kreiss, C., Kotloff, K. L., Porta, N., Blanco, J. L., Bachmann, D., Herranz, M., Saldinger, P. F., Corthesy-Theulaz, I., Losonsky, G., Nichols, R., Simon, J., Stolte, M., Ackerman, S., Monath, T. P., and Blum, A. L. (1999). Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology. 116:804–812.PubMedCrossRefGoogle Scholar
  76. Miyashita, M., Joh, T., Watanabe, K., Todoroki, I., Seno, K., Ohara, H., Nomura, T., Miyata, M., Kasugai, K., Tochikubo, K., Itoh, M., and Nitta, M. (2002). Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori-catalase. Vaccine. 20:2336–2342.PubMedCrossRefGoogle Scholar
  77. Moschos, S. A., Bramwell, V. W., Somavarapu, S., and Alpar, H. O. (2004). Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol. 82:628–637.PubMedCrossRefGoogle Scholar
  78. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., and Steffen, R. (2004). Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 350:896–903.PubMedCrossRefGoogle Scholar
  79. Nervi, G., Liatopoulou, S., Cavallaro, L. G., Gnocchi, A., Dal-Bo, N., Rugge, M., Iori, V., Cavestro, G. M., Maino, M., Colla, G., Franze, A., and Di Mario. F. (2006). Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? A 10 years' endoscopical survey. World J Gastroenterol. 12:2398–2401.PubMedGoogle Scholar
  80. Nurgalieva, Z. Z., Conner, M. E., Opekun, A. R., Zheng, C. Q., Elliott, S. N., Ernst, P. B., Osato, M., Estes, M. K., and Graham, D. Y. (2005). B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect Immun. 73:2999–3006.PubMedCrossRefGoogle Scholar
  81. Pappo, J., Torrey, D., Castriotta, L., Savinainen, A., Kabok, Z., and Ibraghimov, A. (1999). Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun. 67:337–341.PubMedGoogle Scholar
  82. Parsonnet, J., Shmuely, H., and Haggerty, T. (1999). Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA. 282:2240–2245.PubMedCrossRefGoogle Scholar
  83. Perez-Perez, G. I., Dworkin, B. M., Chodos, J. E., and Blaser, M. J. (1988). Campylobacter pylori antibodies in humans. Ann Intern Med. 109:11–17.PubMedGoogle Scholar
  84. Radcliff, F. J., Hazell, S. L., Kolesnikow, T., Doidge, C., and Lee, A. (1997). Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun. 65:4668–4674.PubMedGoogle Scholar
  85. Raghavan, S., Fredriksson, M., Svennerholm, A. M., Holmgren, J., and Suri-Payer, E. (2003). Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol. 132:393–400.PubMedCrossRefGoogle Scholar
  86. Reiner, S. L. (2007). Development in motion: helper T cells at work. Cell. 129:33–36.PubMedCrossRefGoogle Scholar
  87. Rowland, M., Kumar, D., Daly, L., O'Connor, P., Vaughan, D., and Drumm B. (1999). Low rates of Helicobacter pylori reinfection in children. Gastroenterology. 117:336–341.PubMedCrossRefGoogle Scholar
  88. Rupnow, M. F., Shachter, R. D., Owens, D. K., and Parsonnet, J. (2001). Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine. 20:879–885.PubMedCrossRefGoogle Scholar
  89. Satin, B., Del Giudice, G., Della Bianca, V., Dusi, S., Laudanna, C., Tonello, F., Kelleher, D., Rappuoli, R., Montecucco, C., and Rossi, F. (2000). The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med. 191:1467–1476.PubMedCrossRefGoogle Scholar
  90. Sawai, N., Kita, M., Kodama, T., Tanahashi, T., Yamaoka, Y., Tagawa, Y., Iwakura, Y., and Imanishi, J. (1999). Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun. 67:279–285.PubMedGoogle Scholar
  91. Schreiber, S., Konradt, M., Groll, C., Scheid, P., Hanauer, G., Werling, H. O., Josenhans C., and Suerbaum, S. (2004). The spatial orientation of Helicobacter pylori in the gastric mucus. Proc Natl Acad Sci USA. 101:5024–5029.PubMedCrossRefGoogle Scholar
  92. Semino-Mora, C., Doi, S. Q., Marty, A., Simko, V., Carlstedt, I., and Dubois, A. (2003). Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. J Infect Dis. 187:1165–1177.PubMedCrossRefGoogle Scholar
  93. Shi, T., Liu, W. Z., Gao, F., Shi, G. Y., and Xiao, S. D. (2005). Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter. 10:71–79.PubMedCrossRefGoogle Scholar
  94. Smythies, L. E., Novak, M. J., Waites, K. B., Lindsey, J. R., Morrow, C. D., and Smith, P. D. (2005). Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine. 23:901–909.PubMedCrossRefGoogle Scholar
  95. Solnick, J. V., Canfield, D. R., Hansen, L. M., and Torabian, S. Z. (2000). Immunization with recombinant Helicobacter pylori urease in specific-pathogen-free rhesus monkeys (Macaca mulatta). Infect Immun. 68:2560–2565.PubMedCrossRefGoogle Scholar
  96. Sougioultzis, S., Lee, C. K., Alsahli, M., Banerjee, S., Cadoz, M., Schrader, R., Guy, B., Bedford, P., Monath, T. P., Kelly, C. P., and Michetti, P. (2002). Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine. 21:194–201.PubMedCrossRefGoogle Scholar
  97. Strobel S. (2001). Immunity induced after a feed of antigen during early life: oral tolerance v. sensitisation. Proc Nutr Soc 60:437–442.PubMedCrossRefGoogle Scholar
  98. Suda, Y., Kim, Y. M., Ogawa, T., Yasui, N., Hasegawa, Y., Kashihara, W., Shimoyama, T., Aoyama, K., Nagata, K., Tamura, T., and Kusumuto, S. (2001). Chemical structure and biological activity of a lipid A component from Helicobacter pylori strain 206. J Endotoxin Res. 7:95–104.PubMedGoogle Scholar
  99. Suzuki, T., Kato, K., Ohara, S., Noguchi, K., Sekine, H., Nagura, H., and Shimosegawa, T. (2002). Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa. Pathol Int. 52:265–271.PubMedCrossRefGoogle Scholar
  100. Terres, A. M., and Pajares, J. M. (1998). An increased number of follicles containing activated CD69+ helper T cells and proliferating CD71+ B cells are found in H. pylori-infected gastric mucosa. Am J Gastroenterol. 93:579–583.PubMedGoogle Scholar
  101. Todoroki, I., Joh, T., Watanabe, K., Miyashita, M., Seno, K., Nomura, T., Ohara, H., Yokoyama, Y., Tochikubo, K., and Itoh, M. (2000). Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun. 277:159–163.PubMedCrossRefGoogle Scholar
  102. Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., and Schlemper, R. J. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789.PubMedCrossRefGoogle Scholar
  103. Velin, D., Bachmann, D., Bouzourene, H., and Michetti, P. (2005). Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology. 129:142–155.PubMedCrossRefGoogle Scholar
  104. Wolle, K., and Malfertheiner, P. (2007). Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 21:315–324.PubMedCrossRefGoogle Scholar
  105. Yamaguchi, H., Osaki, T., Kai, M., Taguchi, H., and Kamiya S. (2000). Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of Helicobacter pylori. Infect Immun. 68:3448–3454.PubMedCrossRefGoogle Scholar
  106. Zabaleta, J., McGee, D. J., Zea, A. H., Hernandez, C. P., Rodriguez, P. C., Sierra, R. A., Correa, P., and Ochoa, A.C. (2004). Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta). J Immunol. 173:586–593.PubMedGoogle Scholar
  107. Zucca, E., Bertoni, F., Roggero, E., Bosshard, G., Cazzaniga, G., Pedrinis, E., Biondi, A., and Cavalli, F. (1998). Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med. 338:804–810.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Dominique Velin
    • 1
  • Pierre Michetti
    • 1
  1. 1.Service de Gastro-entérologie et d'HépatologieCentre Hospitalier Universitaire Vaudois and University of LausanneLausanneSwitzerland

Personalised recommendations